Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Starting soon Not applicable

Mandala Coloring in Late Pregnancy

NCT07906743 · tracked via the Priya Life Science Turkey tracker
Sponsor
Fidan Balkaya
Phase
Not applicable
Started
2026-11-10
Last updated
2026-10-30

Condition(s) studied

PregnancyAnxietyDepressionPsychological StressSleep Initiation and Maintenance DisordersFear of Childbirth

Investigational drug(s) / intervention(s)

Mandala Coloring Group

Mandala Coloring Group: Participants color two ready-made mandala templates per week for 8 weeks (16 sessions in total, approximately 20-30 minutes each) at home, at a time convenient for them, in a calm and quiet setting. Each participant receives a set of 7-color felt-tip pens and 16 mandala templates of her choice, together with a standard verbal and written briefing on the purpose, duration, session frequency and materials of the intervention. Adherence is monitored through a message sent to the researcher before each session and a photograph of the completed mandala sent afterwards; regular reminder messages are sent throughout the intervention.

Study summary

Anxiety, depression and poor sleep are common in the last months of pregnancy and often occur together. Medication options during pregnancy are limited, so simple, safe non-drug methods are needed. Mandala coloring is an art therapy technique in which a person colors circular patterns; it helps focus attention on the present moment and may have a calming effect.

This randomized controlled trial will examine whether mandala coloring during the third trimester reduces depression, anxiety and stress, improves sleep, and reduces fear of childbirth. It will also look at birth outcomes and the childbirth experience. Pregnant women at 28 weeks of gestation who attend the obstetrics outpatient clinics of Malatya Training and Research Hospital will be randomly assigned to a mandala coloring group or a control group. Women in the mandala group will color two mandalas a week at home for 8 weeks (16 mandalas in total, about 20-30 minutes per session). Women in the control group will receive routine antenatal care only and will be offered the mandala materials after the study ends.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * • Presenting to the Obstetrics and Gynecology Outpatient Clinics of Malatya Training and Research Hospital * Being in the 28th week of gestation * Being 18 years of age or older * Having a singleton, low-risk (healthy) pregnancy * Being able to understand and speak Turkish and being literate * Agreeing to participate in the study voluntarily * Having no physical limitation preventing mandala coloring (being able to use hand and arm movements) Exclusion Criteria: * Having a diagnosed psychiatric disorder or currently using psychotropic medication * Having a diagnosed sleep disorder or currently using sleep medication * Having a visual or cognitive impairment that prevents mandala coloring or completing the questionnaires * Currently participating in another psychological, art-based or mind-body program (e.g., art therapy, yoga, meditation, mindfulness) * Having a diagnosed pregnancy complication (e.g., preeclampsia, gestational diabetes, placenta previa, threatened preterm labor) at enrollment Withdrawal Criteria: * Developing a pregnancy complication requiring hospitalization or giving birth before the posttest assessment * Using any pharmacological or non-pharmacological method for anxiety, depression or sleep problems during the study * Not completing at least 75% of the coloring sessions (12 of 16) in the intervention group * Withdrawing consent at any time

Primary outcome measure(s)

  • Change in Depression Score (DASS-21 Depression Subscale) — aseline (28 weeks of gestation) and after the 8-week intervention (36 weeks of gestation)
    Depression will be assessed with the depression subscale of the Depression Anxiety Stress Scale-21 (DASS-21). The subscale consists of 7 items rated on a 4-point Likert scale (0-3); the subscale score is multiplied by two, giving a range of 0 to 42. Higher scores indicate more severe depression.

Trial sites (1)

FacilityCityRegionStatus
Inonu University Faculty of Nursing Malatya Battalgazi
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07906743 on ClinicalTrials.gov ↗ ← All trials in Turkey